-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

SVB Securities Adjusts Century Therapeutics' Price Target to $14 From $20, Keeps Outperform Rating

SVB Securities Adjusts Century Therapeutics' Price Target to $14 From $20, Keeps Outperform Rating

MT Newswires · 01/06/2023 05:36